Brittenham Marissa 4

What Happened Marissa Brittenham, Chief Strategy Officer of Surgery Partners (SGRY), was granted restricted stock awards on March 5, 2026 totaling 43,230 shares (three separate RSAs) at $14.11 per share (~$610,000 total value). On March 6, 2026 she sold 8,785 shares in an open-market/private sale at $13.70 per share (proceeds ~$120,355) to satisfy tax withholding related to prior RSA vesting. The grants are awards (acquisitions) rather than open‑market purchases.

Key Details

• Grant date(s): March 5, 2026 — three RSAs: 17,717 @ $14.11 ($249,987); 16,363 @ $14.11 ($230,882); 9,150 @ $14.11 ($129,107). Total granted = 43,230 shares (~$609,975).
• Sale: March 6, 2026 — 8,785 shares sold @ $13.70 ($120,355) to cover tax withholding (footnote F1).
• Vesting notes: F2–F4 indicate the RSAs vest on scheduled anniversaries (some in three equal annual installments beginning one year after grant; others vest on the first or second anniversary).
• Shares owned after the transactions: not specified in the provided filing excerpt.
• Filing: Form 4 filed March 9, 2026 (appears timely based on reported transaction dates).

Context

• These were restricted stock awards (RSAs) granted by the company; such awards typically reflect compensation and vest over time and are not the same as an open‑market purchase (which might be considered a stronger bullish signal).
• The sale was a tax‑withholding sale (routine) tied to prior vesting, not necessarily a discretionary sell decision about company prospects.